0.10Open0.05Pre Close71 Volume632 Open Interest54.00Strike Price357.00Turnover4598.97%IV14.88%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0249Delta0.0178Gamma1567.67Leverage Ratio-105.4149Theta0.0000Rho39.04Eff Leverage0.0000Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet